Pharmacoeconomic outcomes of levalbuterol [levosalbutamol] and racemic albuterol [salbutamol] in inpatients requiring nebulization (POLARIS).

Trial Profile

Pharmacoeconomic outcomes of levalbuterol [levosalbutamol] and racemic albuterol [salbutamol] in inpatients requiring nebulization (POLARIS).

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs Levosalbutamol; Salbutamol
  • Indications Acute asthma; Asthma; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms POLARIS
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2008 Results were reported in Clinical Therapeutics.
    • 19 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top